Technical Analysis for CLBS - Caladrius Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical CLBS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -3.23% | |
| NR7 | Range Contraction | -3.23% | |
| Oversold Stochastic | Weakness | -3.23% | |
| Doji - Bullish? | Reversal | -1.64% | |
| Stochastic Reached Oversold | Weakness | -1.64% | |
| Oversold Stochastic | Weakness | -1.64% | |
| Fell Below 20 DMA | Bearish | -1.64% | |
| Shooting Star Candlestick | Bearish | -4.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | 1 day ago |
| Down 1% | 1 day ago |
| Possible NR7 | 2 days ago |
| Possible Inside Day | 2 days ago |
| Fell Below Previous Day's Low | 3 days ago |
Get a Trading Assistant
- Earnings date: 08/11/2021
Caladrius Biosciences, Inc. Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Banking Biopharmaceutical Cancer Immunotherapy Diabetes Cancer Immunotherapy Melanoma Cell Therapy Clinical Services Adult Stem Cell Cord Blood Immunotherapy Product Metastatic Melanoma Progenitor Cell Cancer Immunotherapy Product Infarction Myocardial Infarction Neos Acute Myocardial Infarction Treatment Of Metastatic Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.88 |
| 52 Week Low | 1.15 |
| Average Volume | 295,118 |
| 200-Day Moving Average | 1.64 |
| 50-Day Moving Average | 1.31 |
| 20-Day Moving Average | 1.25 |
| 10-Day Moving Average | 1.24 |
| Average True Range | 0.05 |
| ADX | 17.0 |
| +DI | 19.11 |
| -DI | 20.60 |
| Chandelier Exit (Long, 3 ATRs) | 1.20 |
| Chandelier Exit (Short, 3 ATRs) | 1.29 |
| Upper Bollinger Bands | 1.32 |
| Lower Bollinger Band | 1.18 |
| Percent B (%b) | 0.17 |
| BandWidth | 11.59 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0004 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.26 | ||||
| Resistance 3 (R3) | 1.27 | 1.25 | 1.25 | ||
| Resistance 2 (R2) | 1.25 | 1.24 | 1.25 | 1.25 | |
| Resistance 1 (R1) | 1.23 | 1.23 | 1.22 | 1.22 | 1.24 |
| Pivot Point | 1.21 | 1.21 | 1.21 | 1.21 | 1.21 |
| Support 1 (S1) | 1.19 | 1.20 | 1.18 | 1.18 | 1.16 |
| Support 2 (S2) | 1.17 | 1.19 | 1.17 | 1.15 | |
| Support 3 (S3) | 1.15 | 1.17 | 1.15 | ||
| Support 4 (S4) | 1.14 |
